Neuropeptide FF in the rat spinal cord during carrageenan inflammation

Peptides

Volumn 18, Issue 2, 1997, Pages 287-292

  Kontinen, Vesa K ^a   Aarnisalo, Antti A ^a   Idänpään Heikkilä, Juhana J ^a   Panula, Pertti ^c   Kalso, Eija ^b,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Carrageenan inflammation; Immunohistochemistry; Morphine; Neuropeptide FF; Nociception

Indexed keywords

CARRAGEENAN; NEUROPEPTIDE FF;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; IMMUNOREACTIVITY; INFLAMMATION; MALE; NEUROMODULATION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD;

ANIMALS; CARRAGEENAN; HEAT; INFLAMMATION; MALE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NEURONS; NEUROPEPTIDES; OLIGOPEPTIDES; PAIN; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

ANIMALIA;

EID: 0030952092     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(96)00287-2     Document Type: Article

References (34)

1. Allard M., Theodosis D. T., Rousselot P., Lombard M. C., Simonnet G. Characterization and localization of a putative morphine-modulating peptide, FLFQPQRFamide, in the rat spinal cord: Biochemical and immunocytochemical studies. Neuroscience. 40:1991;81-92.
2. Dubner R., Ruda M. A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15:1992;96-103.
3. Gouarderes C., Sutak M., Zajac J. M., Jhamandas K. Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat. Eur. J. Pharmacol. 237:1993;73-81.
4. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32:1988;77-88.
5. Hassan A. H., Pzewlocki R., Herz A., Stein C. Dynorphin, a preferential ligand for kappa-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat. Neurosci. Lett. 140:1992;85-88.
6. Hylden J. K., Thomas D. A., Iadarola M. J., Nahin R. L., Dubner R. Spinal opioid analgesic effects are enhanced in a model of unilateral inflammation/hyperalgesia: Possible involvement of noradrenergic mechanisms. Eur. J. Pharmacol. 194:1991;135-143.
7. Iadarola M. J., Brady L. S., Draisci G., Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: Stimulus specificity, behavioral parameters and opioid receptor binding. Agents Actions. 25:1988;255-259.
8. Joris J., Costello A., Dubner R., Hargreaves K. M. Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain. 43:1990;95-103.
9. Kavaliers M. Inhibitory influences of mammalian FMRFamide (Phe-Met-Arg-Phe-amide) -related peptides on nociception and morphine- and stress-induced analgesia on mice. Neurosci. Lett. 115:1990;307-312.
10. 2-related peptides and IgG from antiserum against them on aggression and defeat-induced analgesia in mice. Peptides. 12:1991;235-239.
11. 2 -related peptides augments morphine- and stress-induced analgesia in mice. Peptides. 10:1989;741-745.
12. Kivipelto L., Panula P. Origin and distribution of neuropeptide-FF-like immunoreactivity in the spinal cord of rats. J. Comp. Neurol. 307:1991;1-13.
13. 2 -adrenergic and μ -opioid spinal antinociception by neuropeptide FF. Peptides. 16:1995;973-977.
14. Lake J. R., Hammond M. V., Shaddox R. C., Hunsicker L. M., Yang H.-Y. T., Malin D. H. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci. Lett. 132:1991;29-32.
15. Lee C. H., Wasowicz K., Brown R., Majane E. A., Yang H. T., Panula P. Distribution and characterization of neuropeptide FF-like immunoreactivity in the rat nervous system with a monoclonal antibody. Eur. J. Neurosci. 5:1993;1339-1348.
16. Lima D., Esteves F., Coimbra A. C-fos activation by noxious input of spinal neurons projecting to the nucleus of the tractus solitarius in the rat. Gebhart G. F., Hammond D. L., Jensen T. S. Proceedings of the 7th world congress on pain. 1994;423-434 IASP Press, Seattle.
17. 2 with μ and δ opioid antinociception in the rat spinal cord. Neuropeptides. 16:1990;213-218.
18. Millan M. J., Czlonkowski A., Morris B., Stein C., Arendt R., Huber A., Hollt V., Herz A. Inflammation of the hind limb as a model of unilateral, localized pain: Influence on multiple opioid systems in the spinal cord of the rat. Pain. 35:1988;313-326.
19. Oberling P., Stinus L., LeMoal M., Simonnet G. Biphasic effect on nociception and antiopiate activity of the neuropeptide FF (FLFQPQRFamide) in the rat. Peptides. 14:1993;919-924.
20. Presley R. W., Menetrey D., Levine J. D., Basbaum A. I. Systemic morphine suppresses noxious stimulus-evoked fos protein-like immunoreactivity in the rat spinal cord. J. Neurosci. 10:1990;323-335.
21. Przewlocki R., Hassan A. H., Lason W., Epplen C., Herz A., Stein C. Gene expression and localization of opioid peptides in immune cells of inflamed tissue: Functional role in antinociception. Neuroscience. 48:1992;491-500.
22. 2 related peptides on mammals. NIDA Res. Monogr. 105:1991;243-249.
23. Raffa R. B., Connelly C. D. Supraspinal antinociception produced by [D-Met2]-FMRFamide in mice. Neuropeptides. 22:1992;195-203.
24. Raffa R. B., Kim A., Rice K. C., DeCosta B. R., Codd E. E., Rothman R. B. Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid μ , δ , κ1 , κ2A or κ2B receptors. Peptides. 15:1994;401-404.
25. Ren K., Dubner R. NMDA receptor antagonists attenuate mechanical hyperalgesia in rat with unilateral inflammation of the hindpaw. Neurosci. Lett. 163:1993;22-26.
26. Rothman R. B. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse. 12:1992;129-138.
27. Stanfa L., Dickenson A., Xu X.-J., Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: Variations on a theme. Trends Pharmacol. Sci. 15:1994;65-66.
28. Stanfa L. C., Dickenson A. H. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br. J. Pharmacol. 108:1993;967-973.
29. Stanfa L. C., Sullivan A. F., Dickenson A. H. Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation. Pain. 50:1992;345-354.
30. 2 -adrenergic antinociception in the rat dorsal horn in vivo. Brain Res. 562:1991;327-328.
31. 2-like immunoreactivity. Proc. Natl. Acad. Sci. 81:1984;5002-5005.
32. Yaksh T. L., Rudy T. A. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17:1976;1031-1036.
33. Yang H.-Y. T., Fratta W., Majane E. A., Costa E. Isolation, sequencing and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc. Natl. Acad. Sci. 82:1985;7757-7761.
34. Zimmermann M. Ethical guidelines for investigation of experimental pain in conscious animals. Pain. 16:1983;109-110.